Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Captopril and enalapril are both angiotensin-converting enzyme (ACE) inhibitors used to treat hypertension and heart failure. They work by blocking the angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II, which leads to vasodilation, reduced blood pressure, and decreased workload on the heart. While they share the same mechanism of action, they have some differences in pharmacokinetics and clinical effects. Captopril was the first ACE inhibitor approved for clinical use in 1981, while enalapril is a prodrug that requires hepatic biotransformation to form enalaprilat, its active metabolite. Both drugs have been used in the treatment of renal hypertension, often in combination with other medications like furosemide and propranolol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on captopril + enalapril.